Quantification of amikacin and kanamycin in serum using a simple and validated LC-MS/MS method

Bioanalysis. 2014 Aug;6(16):2125-33. doi: 10.4155/bio.14.191.


Background: Amikacin and kanamycin are frequently used in the treatment of multidrug-resistant TB. The current commercially available immunoassay is unable to analyze kanamycin and trough levels of amikacin. The objective was therefore to develop a LC-MS/MS method for the quantification of amikacin and kanamycin in human serum.

Materials & methods: Using apramycin as internal standard, selectivity, accuracy, precision, recovery, matrix effects and stability were evaluated.

Results: The presented LC-MS/MS method meets the recommendations of the US FDA with a low LLOQ of 250 ng/ml for amikacin and 100 ng/ml for kanamycin. No statistical significant difference was found between the LC-MS/MS method and the immunoassay of amikacin (Architect(®) assay, p = 0.501).

Conclusion: The low LLOQ of amikacin and the ability to analyze kanamycin makes the LC-MS/MS method the preferred method for analyzing these aminoglycosides.

MeSH terms

  • Adult
  • Aged
  • Amikacin / blood*
  • Anti-Bacterial Agents / blood*
  • Chromatography, Liquid / methods
  • Drug Monitoring / methods*
  • Female
  • Humans
  • Kanamycin / blood*
  • Male
  • Middle Aged
  • Tandem Mass Spectrometry / methods
  • Young Adult


  • Anti-Bacterial Agents
  • Kanamycin
  • Amikacin